From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder.
Kadek Suhardita, Veno Dwi Krisnanda, Rikas Saputra, Andika Ari Saputra, Agung Slamet Kusmanto
Journal of traumatic stress June 1, 2026 Peer reviewed DOI: 10.1002/jts.70094 via PubMed
Summary
MDMA-assisted psychotherapy shows promise for reducing PTSD symptoms, but significant limitations exist in the current evidence, including issues with blinding and safety monitoring. The commentary emphasizes that future studies should not only focus on symptom reduction but also consider broader recovery indicators like quality of life and the durability of treatment gains. It calls for attention to equity, therapist training, and ethical safeguards for global mental health considerations.
Study at a glance
| Key finding | MDMA-assisted interventions have shown encouraging reductions in PTSD symptoms, but major limitations in the evidence base hinder interpretation and future application. |
|---|
Abstract
In this commentary on Morland et al. (2026)'s recent State of the Science article on 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder (PTSD), we aim to emphasize both MDMA's therapeutic promise and its unresolved scientific challenges. Although recent trials on MDMA-assisted interventions have reported encouraging reductions in PTSD symptoms, the current evidence base remains constrained by several major limitations, including difficulties in blinding, expectancy effects, the absence of robust active comparator conditions, limited mechanistic clarity, and concerns regarding safety monitoring and sample generalizability. This letter argues that these issues are not peripheral but central to the interpretation and future translation of MDMA-assisted psychotherapy. It further highlights the need to move beyond symptom reduction as the primary outcome and incorporate broader indicators of recovery, such as functioning, quality of life, relational restoration, and long-term durability of treatment gains. In addition, we call for stronger attention to equity, scalability, therapist training, and ethical safeguards, particularly if MDMA-assisted psychotherapy is to be considered within a global mental health framework. The discussion aims to stimulate deeper debate on how innovation in trauma treatment should be evaluated before widespread clinical adoption.